| Today's Big NewsMar 13, 2023 |
| By Kevin Dunleavy Scoring two of the three largest M&A deals in biopharma last year was just an appetizer for Pfizer. On Monday, the industry giant sat down to the main course, gobbling up Seattle cancer specialist Seagen for $43 billion. It is the largest acquisition in biopharma since June of 2019, when AbbVie acquired Allergan for $63 billion. |
|
|
|
By Max Bayer President Joe Biden looked to assure Americans that the banking system was safe after U.S. regulators announced they'd backup all depositors of Silicon Valley Bank. The move comes days after a $42 billion bank run tanked the once-heralded startup and biotech financier. |
By Fraiser Kansteiner,Eric Sagonowsky,Zoey Becker,Kevin Dunleavy,Angus Liu The Fierce Pharma team didn't want AbbVie's Humira to have the entire patent-cliff spotlight this year, so we're presenting this special report on the top U.S. losses of exclusivity in 2023. Besides Humira, drugs from J&J, AstraZeneca and more make the list. |
By Andrea Park Illumina is reportedly the target of an upcoming proxy battle, stemming from the sequencing giant’s decision to plow ahead in its $8 billion re-acquisition of former spinout Grail in 2021 in defiance of regulators. |
By James Waldron An antibody-drug conjugate that GSK paid $100 million to license from Mersana Therapeutics has been slapped with a clinical hold after a patient died in the therapy’s first trial. |
By Angus Liu Just as Novartis works to wrap up one massive share buyback program, the company has decided to launch another. Novartis is kicking off a share buyback round that aims to repurchase up to $11 billion in stock over the next three years. |
By Andrea Park The FDA is pushing back on what it has termed “misinformation” swirling around the emergency use authorization it gave one of Lucira Health’s diagnostic tests late last month. |
By James Waldron The U.K.'s BioIndustry Association has praised the government for securing a buyer for the U.K. subsidiary of the failed Silicon Valley Bank. |
By Andrea Park A study published in the journal Respiratory Care this month found that University of Cincinnati startup PEP Buddy’s eponymous device significantly improved COPD patients’ breathlessness caused by physical activity. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines. |
|
|---|
|
|
|
Tuesday, March 21, 2023 | 11am ET / 8am PT Today’s clinical trials are longer and more complex than ever. Sponsors, sites, and patients need technology that is practical, easy to use, and strengthens studies’ scientific integrity. This webinar will explore how approaches from B2B and consumer technologies can be leveraged to streamline processes, deliver quality outcomes data, and more. Register now.
|
|
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
